title: Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia.
authors.forename: L
authors.initials: L
authors.lastname: Laurenti
authors.forename: P
authors.initials: P
authors.lastname: Piccioni
authors.forename: M
authors.initials: M
authors.lastname: Tarnani
authors.forename: P
authors.initials: P
authors.lastname: Chiusolo
authors.forename: N
authors.initials: N
authors.lastname: Piccirillo
authors.forename: C
authors.initials: C
authors.lastname: Rumi
authors.forename: F
authors.initials: F
authors.lastname: Sora
authors.forename: S
authors.initials: S
authors.lastname: Sica
authors.forename: G
authors.initials: G
authors.lastname: Leone
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D016130:Immunophenotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology; D016879:Salvage Therapy
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab